Chlormadinone Acetate (IARC Summary & Evaluation, Volume 6, 1974)

International Agency for Research on Cancer (IARC) - Summaries & Evaluations

CHLORMADINONE ACETATE

VOL.: 6 (1974) (p. 149)

5. Summary of Data Reported and Evaluation

(N.B.: This section should be read in conjunction with the section 'General Conclusions on Hormones'.)

5.1 Animal carcinogenicity data

Chlormadinone acetate was tested by the oral route in mice, rats and dogs. In mice it was also tested in combination with oestrogen.

Given alone, it produced no increase in the incidence of tumours in mice or in rats but resulted in mammary tumours in dogs. The significance of the tumours in dogs is discussed in the section, "General Remarks on the Sex Hormones", in this volume.

In combination with mestranol, the incidence of pituitary tumours was increased in mice of both sexes; in combination with ethinyloestradiol, it increased the incidence of mammary tumours in intact and castrated males of one hybrid strain.

5.2 Human carcinogenicity data

No case reports or epidemiological studies on chlormadinone acetate alone were available to the Working Group. Epidemiological studies on steroid hormones used in oestrogen-progestin contraceptive preparations have been summarized in the section, 'Oestrogens and Progestins in Relation to Human Cancer', in this volume.

Subsequent evaluations: Vol. 21 (1979); Suppl. 7 (1987) (Progestins; Combined oral contraceptives)

Last updated: 18 March 1998




























    See Also:
       Toxicological Abbreviations
       Chlormadinone Acetate (IARC Summary & Evaluation, Volume 21, 1979)